

# **CHIKUNGUNYA VACCINES**

**ACIP Meeting  
October 19, 2022**

**Beth Bell, MD, MPH  
Chair, ACIP Chikungunya Vaccines Work Group**

# Background to formation of Chikungunya Vaccines Work Group

- No chikungunya vaccine ever licensed in United States or globally
- Multiple chikungunya vaccines in development
- One manufacturer initiated rolling submission of BLA to FDA in August 2022 and licensure possible during 2023
- Work Group formed in May 2022

# Purpose of Chikungunya Vaccines Work Group

- To review and evaluate data on chikungunya disease, epidemiology, and vaccines
- To develop policy options for ACIP's consideration for U.S. persons at risk of chikungunya, including
  - Travelers
  - Residents of U.S. territories and states with, or at risk of, transmission

# Terms of Reference for Chikungunya Vaccines Work Group

- To review information on chikungunya disease, including outcomes
- To review data on chikungunya epidemiology and burden among U.S. residents, including travelers and persons living in areas at risk for local transmission
- To review data on safety, immunogenicity, and effectiveness of chikungunya vaccines
- To provide evidence-based recommendation options for ACIP
- To identify areas in need of further research for informing potential future vaccine recommendations
- To publish a chikungunya vaccine MMWR Recommendations and Reports document

# Chikungunya Vaccines Work Group members

## ACIP

Beth Bell, Univ Washington (Chair)

Wilbur Chen, Univ Maryland

## CDC Leads

Susan Hills, DVBD (Lead)

Nicole Lindsey, DVBD (Deputy Lead)

## Ex Officio

Robin Levis, FDA

Sixun Yang, FDA

Lesley Dupuy, NIH

## ACIP Liaisons

Elizabeth Barnett, ISTM

James Campbell, AAP

Mary Pat Friedlander, AAFP

## Invited Consultants

Alan Barrett, Univ Texas Galveston

Carina Blackmore, Florida Dept Health

Alan Lam, DoD

Margaret Ryan, DoD

Steven Schofield, CATMAT

David Shlim, Jackson Hole Travel & Trop Med

Nestor Sosa, Uni New Mexico Hospital

Sanet Torres, San Jorge Children & Women's Hospital

Kirsten Vannice, Bill & Melinda Gates Foundation

Mary Wilson, Univ California San Francisco

# Chikungunya Vaccines Work Group CDC participants

## DVBD

Erin Staples

Ann Powers

Laura Adams

Joshua Wong

## NCEZID

Rita Helfand

## DGMQ

Sarah Guagliardo

## DHQP

Michael McNeil

## Global Immunization Division

Rebecca Casey

Susan Chu

## ISD

Elisabeth Velazquez

## GRADE/ETR consultants

Doug Campos-Outcalt

Rebecca Morgan

## ACIP Secretariat

Jessica MacNeil, NCIRD

# Today's session

- Overview of chikungunya disease and vaccines
  - Dr. Susan Hills (CDC/NCEZID)
- Immunogenicity and safety of Valneva's chikungunya vaccine
  - Dr. Katrin Dubishar (Valneva)
- Work Group interpretation of vaccine data and Work Group plans and timelines
  - Dr. Susan Hills (CDC/NCEZID)